"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. The partnership will leverage AMD Instinct accelerators and ROCm software ...

Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software “We are proud ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...